



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

29 Mar 2021 (#08)

*[Click on blue [hyperlink](#) for further information]*

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizek@sun.ac.za](mailto:lizek@sun.ac.za)

## Important Notices

- [NOT-HD-21-019](#) Notice of Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Participation in PA-20-183, "Research Project Grant (Parent R01 Clinical Trial Required)"
- [NOT-HD-21-020](#) Notice of NICHD Participation on PA-20-184 "Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)"
- [NOT-MH-21-220](#) Notice of Change to Key Dates of RFA-MH-21-120, "Mental Health Research Awards for Investigators Early in their Career in Low and Middle-Income Countries (R01 Clinical Trial Optional)"

## Notices of Special Interest (NOSI)

[NOT-AI-21-032](#) **Investigations on Inborn Errors of Immunity/Primary Immunodeficiencies.** This NOSI is to support the discovery and characterization of Inborn Errors of Immunity, also referred to as Primary Immunodeficiencies, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders. This notice applies to due dates on or after 5 June 2021 and subsequent receipt dates through 7 May 2024. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs)

- [PA-20-185](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-195](#) - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-200](#) - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)

[NOT-TW-21-003](#) **Administrative Supplements for COVID-19-Impacted FIC Research Training and Education Awards.** This Notice outlines priorities for supplemental funding from the Fogarty International Center for active research training and education awards (e.g., D43, U2R, R25) that are in the last year of funding and have been significantly impacted by the COVID-19 pandemic. The Fogarty International Center recognizes that investigators have experienced significant research training delays and interruptions, which have especially limited progress in research training and education efforts in low- and middle- income countries (LMICs). To stretch this funding, the FIC asks that other solutions and sources of funding be considered and exhausted before requesting additional funds and that investigators apply only in cases of significant need. FIC will only consider administrative supplements in the last year of the parent award (with the last year of the parent award beginning on or before May 1, 2021). Application Due Date – May 14, 2021 by 5:00 PM local time of applicant organization. Budget: Maximum \$50,000 (direct costs). Budget requests must be justified in detail and include more than one budget category. The application budget is limited to 1 year only.

[NOT-TW-21-004](#) **Administrative Supplements to FIC Awards for COVID-19-related Research in Low- or Middle-Income Countries.** This Notice describes priorities for supplemental funding from the Fogarty International Center (FIC) for active FIC awards (i.e., not awards administered by other NIH ICs with FIC co-funding) to support COVID-19-related research or mentored research projects on scientific questions unique to low- and middle-income countries (LMICs). This NOSI is **not** intended to support COVID-19-impacted research. The parent award must be active (i.e., not in a no-cost or funded extension) when the supplemental application is submitted regardless of the time

remaining on the current project. Application Due Date – May 14, 2021 by 5:00 PM local time of applicant organization. **Budget:** Requests must not exceed \$75,000 direct costs. The requested budget should support research or research training costs at the LMIC performance site. The application budget is limited to 1 year only.

**[NOT-HL-21-008 Stimulate Research on the Diagnosis, Treatment, and Mechanistic Understanding of Postural Orthostatic Tachycardia Syndrome \(POTS\)](#)** Individuals with Postural Orthostatic Tachycardia Syndrome (POTS) suffer from an excessive increase in heart rate (tachycardia) and other symptoms that worsen upon standing or sitting up, such as light-headedness, shortness of breath, chest pain, and palpitations. It is likely that POTS has multiple underlying mechanisms resulting in subtypes of POTS that need to be identified and characterized. This notice applies to due dates on or after June 5, 2021 and subsequent receipt dates through May 7, 2024. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.

- [PA-20-183](#) - NIH Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-185](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Funding Opportunity Announcements (FOA)

### 1. Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-21-166](#)

**Type:** R01

**Application Due Date:** June 05, 2021, October 05, 2021, February 05, 2022, June 05, 2022. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines "innovation" as likelihood to deliver a new capability to end users.

**Budget:** Application budgets are limited to \$499,000 (direct costs) per year. The maximum project period is 5 years.

### 2. Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-21-206](#)

**Type:** R01

**Application Due Date:** June 05, 2021, October 05, 2021, February 05, 2022, June 05, 2022. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and

validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines "innovation" as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. This FOA is not intended to support straight clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA. This FOA does not propose to support commercial production or basic research projects.

**Budget:** Application budgets are limited to \$499,000 (direct costs) per year. The maximum project period is 5 years.

### 3. Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-21-183](#)

**Type:** UG3/UH3

**Application Due Date:** September 08, 2021, January 10, 2022, September 08, 2022, January 10, 2023. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). Advances in technology offer unprecedented opportunities to develop clinical-grade mobile, web, or other software-based platforms designed to deliver treatments that are safe and effective for SUD. FDA authorization of DTx can play an important role in increasing the availability of treatments to patients with SUD. The primary objective of this FOA is to move DTx to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications. The UG3/UH3 Cooperative Agreement involves 2 phases. The UG3 phase, for up to 2 years, is designed to support a project with specific milestones to be accomplished by the end of the period. The UH3 phase is to provide funding for up to 3 additional years following successful completion of the UG3. UG3 projects that meet their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators submitting to this FOA must address both UG3 and UH3 phases.

**Budget:** Application budgets are limited to \$500,000 direct costs for each year of the UG3 phase, but are not limited for the UH3 phase. However, budgets need to reflect the actual needs of the proposed project. The project period is limited to 2 years for the UG3 phase and 3 years for the UH3 phase.

### 4. Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-21-208](#)

**Type:** R21

**Application Due Date:** August 10, 2021; February 15, 2022; August 10, 2022; February 15, 2023 Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking.

**Budget:** The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$150,000 in direct costs may be requested in any single year.

### 5. Strategies that Support Global Food Safety (U01) Clinical Trial Not Allowed

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-FDA-21-030](#)

**Type:** U01

**Application Due Date:** May 24, 2021, by 11:59 PM Eastern Time.

**Funding Opportunity Announcement:** FDA announces its intention to accept and consider a single source application for award of a cooperative agreement to the World Health Organization (WHO) Department of Food Safety and Zoonoses (FOS) to support strategies that address global food safety. This Cooperative Agreement is expected to contribute to the knowledge base of the current state of food safety and its accompanying scientific research to a global audience, including challenges, risks and emerging food safety trends, and other food safety research based on WHO's existing network efforts, such as the Global Foodborne Infections Network (GFN), International Food Safety Authorities Network (INFOSAN), Global Environment Monitoring System for Food (GEMS/Food); Global Early Warning Systems for Animal Diseases Including Zoonoses (GLEWS); Foodborne Disease Burden Epidemiology Reference Group (FERG); Enable the sharing of scientific research findings and data through expert meetings, informational documents summarizing the latest research, investigations, studies, and technical consultations; Enhance capacity at international and national levels in such areas of laboratory analyses and scientific research engagement, surveillance, and risk assessment/risk management, including through the Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR); Contribute to the scientific, standard-setting work of the Codex Alimentarius Commission (Codex) through scientific advisory groups including the Joint Food and Agriculture Organization of the United Nations (FAO)/WHO Expert Committee on Food Additives (JECFA), the Joint FAO/WHO Meetings on Pesticide Residues (JMPR), the FAO/WHO Joint Meetings on Microbiological Risk Assessment (JEMRA), and the Joint FAO/WHO Expert Meetings on Nutrition (JEMNU) currently in development phase; Food safety projects (including the promotion of current scientific research) of mutual interest, and Enable participation of Member States through the Codex Trust Fund.

**Budget:** Application budgets need to reflect the actual needs of the proposed project and should not exceed the following in total costs (direct and indirect): \$1,000,000 per year. The scope of the proposed project should determine the project period. The maximum project period is five (5) years.

## 6. Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) – Research (Collaborative U01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-TW-21-001](#)

**Type:** U01

**Application Due Date:** July 08, 2021. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) solicits applications for research projects in linked Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth). The overall objective of the GEOHealth program is to support the development of institutions in Low- or Middle-Income Countries (LMICs) that will serve as regional hubs for collaborative research, data management, research training, curricula and outreach material development, and policy support around high priority local, national, and regional environmental and occupational health threats. These hubs are expected to conduct the research and training needed to identify and design mitigation strategies for the adverse consequences of environmental exposures and inform relevant policy development in LMICs. The global network of hubs will serve as a platform for coordinated research and research training. GEOHealth Hubs are expected to provide leadership in environmental and occupational health research and in training a new generation of environmental and occupational health experts. Hubs are supported by two coordinated linked awards to 1) a LMIC institution for research and 2) a U.S. institution for research training. Both applications must demonstrate a commitment to extensive coordination between these two awards to meet goals of the GEOHealth program. An application submitted in response to this FOA for research must be harmonized with a linked application for research training under [RFA-TW-21-002](#) “Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) – Research Training (Collaborative U2R Clinical Trial Optional)”. This research FOA is intended to support collaborative research that contributes to the long-term goals of 1) building and strengthening sustainable research capacity in LMICs to address environmental and occupational health, and 2) developing a research foundation to inform evidence-based policy related to environmental and occupational health. Clinical research (<https://grants.nih.gov/grants/glossary.htm#ClinicalResearch>), clinical trials (<https://grants.nih.gov/grants/glossary.htm#ClinicalTrial>), and human subjects research (<https://humansubjects.nih.gov/>) are allowed under this FOA. Examples of the types of NIH-defined clinical trials that could be proposed include (but are not limited to) technology interventions, behavioral interventions, etc. This FOA will NOT support studies whose purpose is to evaluate safety clinical efficacy, effectiveness, and management and/or implementation of new or established pharmacological agents. For the NIH definition of clinical research versus clinical trials, please see <https://grants.nih.gov/policy/clinical-trials/definition.htm>. Please use the clinical trial tool (<https://grants.nih.gov/ct-decision/index.htm>) to determine whether your proposed study is a clinical trial. For additional information please refer to the [NIH Clinical Trials Requirements](#) and [Fogarty information on human subjects research and clinical trials](#). Applicants desiring to conduct NIH-defined clinical trials should contact the FIC prior to submission to review the scope of the proposed clinical trial with the program contact. Applicants are strongly encouraged to review the [NOT-OD-15-103](#) on enhancing the reproducibility of NIH-supported research through rigor and transparency and to incorporate appropriate features into the proposed research plans.

**Budget:** FIC and partner components intend to commit an estimated total of \$4.2 million for FY2022 for the combined linked (U01 and U2R) awards, corresponding to approximately seven linked hub awards. The application budget should be developed in close coordination with the linked U2R research training application ([RFA-TW-21-002](#)) because the combined budget for both linked applications cannot exceed \$600,000 in total costs per year (including 8% F&A), and at least 50% of the combined budget must be in the LMIC's U01 application. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

## 7. Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) – Research Training (Collaborative U2R Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-TW-21-002](#)

**Type:** U2R

**Application Due Date:** July 8, 2021. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) solicits applications for research training activities in linked Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth). The overall objective of the GEOHealth program is to support the development of institutions in the Low- or Middle-Income Countries (LMICs) that will serve as regional hubs for collaborative research, data management, research training, curricula and outreach material development, and policy support around high priority local, national, and regional environmental and occupational health threats. These hubs are expected to conduct the research and training needed to identify and design mitigation strategies for the adverse consequences of environmental exposures and inform relevant policy development in LMICs. The global network of hubs will serve as a platform for coordinated research and research training. GEOHealth Hubs are expected to provide leadership in environmental and occupational health research and in training a new generation of environmental and occupational health experts. Hubs are supported by two coordinated linked awards to 1) a LMIC institution for research and 2) a U.S. institution for research training. Both applications must demonstrate a commitment to extensive coordination between these two awards to meet goals of the GEOHealth program. An application submitted in response to this FOA for research training must be harmonized with a linked application for related research under [RFA-TW-21-001](#) “Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) – Research (Collaborative U01 Clinical Trial Optional)”. This research training FOA is intended to support research training of LMIC investigators, provide mentored research training opportunities in the partner LMIC, and strengthen the capacity of the partner LMIC institution to conduct environmental and occupational health research. This Funding Opportunity Announcement (FOA) allows appointment of Trainees proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

**Budget:** Anticipated budget total costs may not exceed \$300,000 per year. The U2R application budget should be developed in close coordination with the linked U01 research application ([RFA-TW-21-001](#)) because the combined budget for both linked U01 and U2R applications cannot exceed \$600,000 in total costs per year (including 8% F&A) and at least 50% of the combined budget must be in the LMIC's U01 application. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105